We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+19.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$755M
AUM Growth
-$138M
Cap. Flow
-$136M
Cap. Flow %
-17.97%
Top 10 Hldgs %
75.28%
Holding
43
New
3
Increased
4
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$8.53M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.02M
3
CMPS
Compass Pathways
CMPS
+$6.74M
4
ETNB
89bio
ETNB
+$3.29M
5
SRZN icon
Surrozen
SRZN
+$3.02M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$89.3M
2
VRNA
Verona Pharma
VRNA
+$50.6M
3
DCTH icon
Delcath Systems
DCTH
+$13.6M
4
RGLS
Regulus Therapeutics
RGLS
+$3.04M
5
RZLT icon
Rezolute
RZLT
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$319M 42.19%
4,458,294
-1,833,557
-29% -$89.3M
VRNA
2
DELISTED
Verona Pharma
VRNA
$91.3M 12.1%
1,438,785
-845,190
-37% -$50.6M
GERN icon
3
Geron
GERN
$930M
$43.3M 5.73%
27,225,292
– –
TRVI icon
4
Trevi Therapeutics
TRVI
$2.62B
$21.9M 2.91%
3,487,903
– –
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$21M 2.78%
2,684,109
– –
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$19M 2.52%
6,895,746
– –
CDTX
7
DELISTED
Cidara Therapeutics
CDTX
$14.7M 1.95%
684,276
+13,676
+2% +$304K
ACRS icon
8
Aclaris Therapeutics
ACRS
$744M
$13.6M 1.8%
8,888,888
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.15B
$13.2M 1.75%
982,576
– –
DYN icon
10
Dyne Therapeutics
DYN
$4.28B
$11.7M 1.54%
1,114,960
– –
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.23B
$11.6M 1.54%
2,080,450
+802,632
+63% +$7.02M
TIL icon
12
Instil Bio
TIL
$49.4M
$10.2M 1.35%
585,485
– –
CMPS
13
Compass Pathways
CMPS
$1.46B
$9.62M 1.27%
3,362,385
+1,754,385
+109% +$6.74M
DCTH icon
14
Delcath Systems
DCTH
$399M
$9.55M 1.26%
750,195
-958,384
-56% -$13.6M
ZBIO
15
Zenas BioPharma
ZBIO
$2.04B
$9.35M 1.24%
1,183,260
– –
VSTM icon
16
Verastem
VSTM
$547M
$9.28M 1.23%
1,538,461
– –
ERAS icon
17
Erasca
ERAS
$6.3B
$9.26M 1.23%
6,756,756
– –
DRUG
18
Bright Minds Biosciences
DRUG
$706M
$9.07M 1.2%
251,572
– –
TRML
19
DELISTED
Tourmaline Bio
TRML
$9M 1.19%
591,882
– –
ABEO icon
20
Abeona Therapeutics
ABEO
$343M
$8.77M 1.16%
1,842,751
– –
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$8.29M 1.1%
1,552,685
– –
AKRO
22
DELISTED
Akero Therapeutics
AKRO
$8.14M 1.08%
+201,168
New +$8.53M
CRVS icon
23
Corvus Pharmaceuticals
CRVS
$1.12B
$7.11M 0.94%
2,234,566
– –
CMPX icon
24
Compass Therapeutics
CMPX
$367M
$6.76M 0.89%
3,556,023
– –
IOBT
25
DELISTED
IO Biotech
IOBT
$6.73M 0.89%
6,173,439
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Vivo Capital held 43 positions worth $755M, down 15% from $893M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Vivo Capital withdrew a net $136M in Q1 2025, closing 3 positions and reducing 7 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $1.97M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Akero Therapeutics worth $8.14M.

  • Vivo Capital's largest Q1 2025 buy was Akero Therapeutics: 201,168 shares worth $8.14M.
  • Vivo Capital added most to Oric Pharmaceuticals in Q1 2025, an estimated $7.02M increase.
  • Vivo Capital's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $89.3M.
  • Vivo Capital fully exited Corbus Pharmaceuticals in Q1 2025, selling an estimated $1.97M.
  • Vivo Capital's ten largest holdings make up 75% of its $755M portfolio in Q1 2025.
  • Vivo Capital opened 3 new positions and closed 3 in Q1 2025.
  • Vivo Capital's portfolio value fell 15% quarter-over-quarter to $755M.

Based on Vivo Capital's 13F filing for Q1 2025, filed 12 May 2025.